Literature DB >> 22870108

Novel disubstituted chrysene as a potent agent against colon cancer.

Bimal K Banik1, Manas K Basu, Fredrick F Becker.   

Abstract

Research on polycyclic aromatic hydrocarbons and their derivatives has received significant attention from the scientific community. The present study involved the synthesis of several novel 6,12-disubstituted chrysene derivatives. Nitration of chrysene with nitric acid produced 6,12-dinitrochrysene which when reduced yielded 6,12-diaminochrysene. A coupling reaction of 6,12-diaminochrysene with an acid in the presence of isobutylchloroformate produced amide. The reduction of amide produced an amine. The amino was converted to a hydrochloride salt. The new compounds were characterized through different types of analytical data. One of these compounds demonstrated marked activity in vivo against a colon cancer cell line. Inhibition of the growth of this tumor was best noted at day 20 when each treatment regimen inhibited the average tumor volume by 50%. In a number of in vivo tests in various regimens, the hydrochloride salt demonstrated consistent inhibition of the growth of the cancer HT-29 cell line. Despite the research progress in polycyclic aromatic compounds, the use of these types of molecules as anticancer agents has not been reported systematically.

Entities:  

Year:  2010        PMID: 22870108      PMCID: PMC3412534          DOI: 10.3892/ol.2010.167

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  8 in total

1.  Polycyclic aromatic compounds as anticancer agents: structure-activity relationships of chrysene and pyrene derivatives.

Authors:  B K Banik; F F Becker
Journal:  Bioorg Med Chem       Date:  2001-03       Impact factor: 3.641

2.  2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.

Authors:  K W Bair; C W Andrews; R L Tuttle; V C Knick; M Cory; D D McKee
Journal:  J Med Chem       Date:  1991-07       Impact factor: 7.446

3.  Evaluation of amonafide in cervical cancer, phase II. A SWOG study.

Authors:  V K Malviya; P Y Liu; D S Alberts; E A Surwit; J B Craig; E V Hannigan
Journal:  Am J Clin Oncol       Date:  1992-02       Impact factor: 2.339

4.  Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of dibenzofluorene derivatives.

Authors:  F F Becker; C Mukhopadhyay; L Hackfeld; I Banik; B K Banik
Journal:  Bioorg Med Chem       Date:  2000-12       Impact factor: 3.641

5.  Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.

Authors:  W A Denny; G W Rewcastle; B C Baguley
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

6.  Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicin.

Authors:  T Fukushima; Y Kawai; T Nakayama; T Yamauchi; A Yoshida; Y Urasaki; S Imamura; K Kamiya; H Tsutani; T Ueda; T Nakamura
Journal:  Oncol Res       Date:  1996       Impact factor: 5.574

7.  Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.

Authors:  S M Sami; R T Dorr; A M Sólyom; D S Alberts; W A Remers
Journal:  J Med Chem       Date:  1995-03-17       Impact factor: 7.446

8.  Stereoselective synthesis of beta-lactams with polyaromatic imines: entry to new and novel anticancer agents.

Authors:  Indrani Banik; Frederick F Becker; Bimal K Banik
Journal:  J Med Chem       Date:  2003-01-02       Impact factor: 7.446

  8 in total
  1 in total

1.  Polycyclic aromatic compounds as anticancer agents: Evaluation of synthesis and in vitro cytotoxicity.

Authors:  Debasish Bandyopadhyay; Jose C Granados; John D Short; Bimal K Banik
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.